- Home
- AVTX vs PBYI Comparison
AVTX vs PBYI Comparison
Compare AVTX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- PBYI
- Stock Information
- Founded
- AVTX 2011
- PBYI 2010
- Country
- AVTX United States
- PBYI United States
- Employees
- AVTX N/A
- PBYI N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- PBYI Health Care
- Exchange
- AVTX Nasdaq
- PBYI Nasdaq
- Market Cap
- AVTX 248.3M
- PBYI 263.4M
- IPO Year
- AVTX 2015
- PBYI N/A
- Fundamental
- Price
- AVTX $18.62
- PBYI $5.05
- Analyst Decision
- AVTX Strong Buy
- PBYI Strong Buy
- Analyst Count
- AVTX 9
- PBYI 1
- Target Price
- AVTX $30.14
- PBYI $7.00
- AVG Volume (30 Days)
- AVTX 351.6K
- PBYI 679.3K
- Earning Date
- AVTX 11-06-2025
- PBYI 11-06-2025
- Dividend Yield
- AVTX N/A
- PBYI N/A
- EPS Growth
- AVTX N/A
- PBYI 59.87
- EPS
- AVTX N/A
- PBYI 0.74
- Revenue
- AVTX $192,000.00
- PBYI $211,995,000.00
- Revenue This Year
- AVTX N/A
- PBYI N/A
- Revenue Next Year
- AVTX N/A
- PBYI N/A
- P/E Ratio
- AVTX N/A
- PBYI $6.77
- Revenue Growth
- AVTX N/A
- PBYI N/A
- 52 Week Low
- AVTX $3.39
- PBYI $2.58
- 52 Week High
- AVTX $19.41
- PBYI $6.12
- Technical
- Relative Strength Index (RSI)
- AVTX 64.08
- PBYI 50.87
- Support Level
- AVTX $16.75
- PBYI $4.89
- Resistance Level
- AVTX $19.29
- PBYI $5.10
- Average True Range (ATR)
- AVTX 1.41
- PBYI 0.38
- MACD
- AVTX 0.17
- PBYI -0.01
- Stochastic Oscillator
- AVTX 87.31
- PBYI 31.72
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.